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Abstract Increasing evidence has indicated that activated gli-
al cells releasing nociceptive factors, such as interleukins and
chemokines, are of key importance for neuropathic pain.
Significant changes in the production of nociceptive factors
are associated with the low effectiveness of opioids in neuro-
pathic pain. Recently, it has been suggested that CCL2/CCR2
signaling is important for nociception. Here, we studied the
time course changes in the mRNA/protein level of CD40/Iba-
1, CCL2 and CCR2 in the spinal cord/dorsal root ganglia
(DRG) in rats following chronic constriction injury
(CCI) of the sciatic nerve. Moreover, we examined the
influence of intrathecal preemptive and repeated (daily
for 7 days) administration of RS504393, CCR2 antago-
nist, on pain-related behavior and the associated bio-
chemical changes of some nociceptive factors as well
as its influence on opioid effectiveness. We observed
simultaneous upregulation of Iba-1, CCL2, CCR2 in
the spinal cord on 7th day after CCI. Additionally, we
demonstrated that repeated administration of RS504393
not only attenuated tactile/thermal hypersensitivity but
also enhanced the analgesic properties of morphine and
buprenorphine under neuropathy. Our results proof that
repeated administration of RS504393 reduced the mRNA
and/or protein levels of pronociceptive factors, such as IL-
1beta, IL-18, IL-6 and inducible nitric oxide synthase
(iNOS), and some of their receptors in the spinal cord and/or
DRG. Furthermore, RS504393 elevated the spinal protein lev-
el of antinociceptive IL-1alpha and IL-18 binding protein. Our
data provide new evidence that CCR2 is a promising target for
diminishing neuropathic pain and enhancing the opioid anal-
gesic effects.
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Introduction
The treatment of neuropathic pain is a serious clinical prob-
lem, mainly because of poor responses and numerous unde-
sired adverse effects of opioids that are commonly used in
high doses. Pain associated with neuropathy develops as a
result of central and/or peripheral nervous system damage;
however, the detailed mechanism of its development remains
unclear. Undoubtedly, alongside neuronal pathways, activated
glial cells that produce nociceptive factors, such as interleu-
kins and chemokines, are of key importance for pain transmis-
sion under neuropathy (Gao and Ji 2010; Kiguchi et al. 2012;
Old et al. 2015). Until now, it has been well established that
the disrupted equilibrium between pro- and antinociceptive
factors contributes to the development of neuropathic pain
(Rojewska et al. 2014b; Pilat et al. 2015, 2016).
Severa l s tud ies have shown tha t in t ra theca l /
intracerebroventricular injections of IL-1beta (Oka et al.
1994; Mika et al. 2008) and IL-6 (Oka et al. 1995) induced
pain-related behavior, whereas intrathecal administration of
IL-1alpha (Mika et al. 2008), IL-1 receptor antagonist (IL-
1RA) (Milligan et al. 2006; Ledeboer et al. 2007; Pilat et al.
2015) and IL-18 binding protein (IL-18BP) (Pilat et al. 2016)
attenuated neuropathic pain in rats. Moreover, it was recently
reported that intrathecal IL-10 gene therapy resulted in pro-
found neuropathic pain relief in several animal models
(Milligan et al. 2006; Ledeboer et al. 2007). Previous studies
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have also shown that intracerebroventricular injections of ex-
ogenous IL-1beta reduced the analgesic effect of morphine
(Gul et al. 2000; Rady and Fujimoto 2001), whereas chronic
administration of IL-1RA (Pilat et al. 2015), IL-18BP
(Pilat et al. 2016), sTNFR, and anti-IL-6 antibody
(Raghavendra et al. 2002) partially restored morphine
efficacy in neuropathic rats. Additionally, a single intrathecal
injection of IL-1RA and IL-18BP improved the analgesic ef-
ficiency of both morphine and buprenorphine in sciatic nerve-
injured rats (Pilat et al. 2015, 2016).
Both interleukins and chemokines are involved in
pain processing (Gao and Ji 2010; Old and Malcangio
2012; Kwiatkowski et al. 2016). It has already been
shown that C-C motif chemokine ligand 2 (CCL2;
Monocyte Chemoattractant Protein-1; MCP-1) and its
receptor C-C chemokine receptor type 2 (CCR2) play
crucial roles in neuropathic pain development (Gao
and Ji 2010; Van Steenwinckel et al. 2011; Zhang
et al. 2012). Piotrowska et al. (2016a) provided evi-
dence that RS504393 decreased pain-related behavior
in rats following chronic constriction injury by reducing
microglial activation and spinal upregulation of CCL2
and CCR2.
The first aim of our study was to examine time course
changes in the mRNA and protein level of CD40/Iba-1,
CCL2 and CCR2 in the spinal cord and dorsal root ganglia
(DRG) in rats following chronic constriction injury (CCI) of
the sciatic nerve. The second object of our study was to
examine how the RS504393, CCR2 antagonist, influ-
ences tactile and thermal hypersensitivity in CCI-
exposed rats. The next goal was to examine the impact
of the repeated intrathecal administration of the RS504393 on
the protein level of Iba-1, CD4 and CD8, as well as mRNA
and protein levels of pronociceptive (IL-1beta, IL-18, IL-6,
and iNOS) and antinociceptive (IL-1alpha, IL-1RA, IL-
18BP, and IL-10) factors in the spinal cord and DRG
during neuropathic pain, thereby to enhance our knowl-
edge regarding its analgesic mechanism of action. The
final aim of our study was to examine how and if
RS504393 influences the analgesic effects of morphine
and buprenorphine in rats following chronic constriction
injury to the sciatic nerve.
Materials and Methods
Animals and Ethical Statement
Adult male Wistar rats (250–300 g) from Charles River
Laboratories International, Inc. (Germany) were used in our
experiments. Rats were housed in cages lined with sawdust
under a standard 12/12 h light/dark cycle (lights on at
8.00 a.m.) with food and water available ad libitum.
Animals were allowed to acclimate to the environment for
approximately 5 min prior to behavioral testing. All experi-
ments were performed according to the recommendations of
the International Association for the Study of Pain (IASP)
(Zimmermann 1983) and the National Institutes of Health
(NIH) Guide for the Care and Use of Laboratory Animals.
The study protocol was approved by the II Local Bioethics
Committee branch of the National Ethics Committee for
Experiments on Animals based at the Institute of
Pharmacology, Polish Academy of Sciences (Krakow,
Poland).
Intrathecal Implantation of Catheters
Catheters for intrathecal (i.t.) injections were implanted ac-
cording to the method described by Yaksh and Rudy (1976)
and our earlier publications (Popiolek-Barczyk et al. 2015;
Rojewska et al. 2015; Piotrowska et al. 2016a). Just before
operation each rat was anesthetized with sodium pentobarbital
(60 mg/kg) administered intraperitoneally (i.p.). The i.t. cath-
eter consisted of 13 cm-long polyethylene tubing (PE 10,
Intramedic; Clay Adams, Parsippany, NJ, USA) with the dead
space of 10 μl sterilized by immersion in 70% (v/v) ethanol
and fully flushed with aqua pro injectione before insertion.
Then, 7.8 cm of catheter was carefully introduced through the
atlanto-occipital membrane and advanced into the subarach-
noid space at the rostral level of the spinal cord lumbar en-
largement (L4-L5). The first injection of water (10 μl) was
slowly performed after implantation, and the catheter was
tightened. All rats were allowed to recover from surgery for
one week before creating the neuropathic pain model.
Chronic Constriction Injury of the Sciatic Nerve in Rats
Chronic constriction injury (CCI) of the sciatic nerve
was performed under sodium pentobarbital anesthesia
(60 mg/kg, i.p.) according to the procedure described
by Bennett and Xie (1988). First, an incision below
the hipbone was made, and then the biceps femoris
and gluteus superficialis were separated. After exposing
the right sciatic nerve, four ligatures (4/0 silk) were
loosely tied around the nerve at 1-mm spacing until a
brief twitch in the operated hind limb was elicited. All
rats developed long-lasting neuropathic pain. In previous
research, we showed that there is no significant differ-
ence in the nociceptive responses as well as the level of
nociceptive factors between naive and sham-operated
animals (e.g., IL-18, IL-6, and IL-1 beta protein levels
were 1 ± 0.2 vs. 0.9 ± 0.2, 1 ± 0.1 vs. 1.1 ± 0.1, 1 ± 0.1 vs.
1.12 ± 0.1, respectively), and therefore we used naive
animals for the behavioral experiments in the current
study (Rojewska et al. 2015).
Behavioral Tests
Tactile Hypersensitivity Measurement
Tactile hypersensitivity in the rats was measured using an
automatic von Frey apparatus (Dynamic Plantar
Aesthesiometer Cat. No. 37400, Ugo Basile, Italy). The ani-
mals were placed in plastic cages with a wire net floor 5 min
before the experiment. Von Frey filaments were applied in
increasing values (up to 26 g) to the midplantar surface of
the hind paw, and measurements were taken automatically,
as described previously (Mika et al. 2010; Makuch et al.
2013). The ipsilateral paw was tested two times in 2 min in-
tervals, and the mean value was calculated.
Thermal Hypersensitivity Measurement
Thermal hypersensitivity was assessed using a cold plate ap-
paratus (Cold/Hot Plate Analgesia Meter No. 05044,
Columbus Instruments, USA). The animals were placed on
the cold plate, and the latency to lift the hind paw was record-
ed. The temperature of the plate was kept at 5 °C, and the cut-
off latency was 30 s. In all cases, the injured paw reacted first
(Mika et al. 2007; Makuch et al. 2013).
Drug Administration
Following substances were used in this study: RS504393 (RS;
Tocris, Warsaw, Poland), morphine hydrochloride (M; TEVA,
Kutno, Poland), and buprenorphine (B; Polfa Warszawa S.A.,
Warsaw, Poland). RS (20 μg/5 μl) was dissolved in 12%
DMSO and intrathecally administered preemptively at 16 h
and 1 h before CCI and then once a day for 7 days or only once
on the 7th day post-CCI. The control group received vehicle
(V; 12% DMSO) at the same schedule. The concentration of
examined substances were selected according to the literature
(Zhu et al. 2014; Piotrowska et al. 2016a) and our preliminary
study. The dosing schedule (Scheme 1) was selected basing on
our previous research, which demonstrated that substances
which may modulate microglial cells need to be administered
preemptively (Rojewska et al. 2015; Kwiatkowski et al. 2016;
Jurga et al. 2016) as the activated microglia is very difficult to
fade out afterwards. Respective substances were slowly deliv-
ered in a volume of 5 μl via the i.t. catheter and followed by
10 μl of aqua pro injectione. The behavioral tests were per-
formed 7 days after CCI always in the same order, firstly von
Frey test and then cold plate test (similarly to our previous
papers Mika et al. 2008; Makuch et al. 2013; Rojewska
et al. 2014a; Kwiatkowski et al. 2016; Pilat et al. 2016;
Rojewska et al. 2016; Zychowska et al. 2016), 30 min and
35 min after the last drug injection, respectively. On the 7th
day post-CCI, chronically V-treated and RS-treated rats re-
ceived a single dose of morphine or buprenorphine (2.5 μg/
5 μl) 60 min after RS504393/vehicle injection, and then, both
behavioral tests were repeated.
Biochemical Tests
Analysis of Gene Expression (RT-qPCR)
Ipsilateral fragments of the dorsal part of the lumbar (L4-L6)
spinal cord and the DRG (L4-L6) were collected immediately
after decapitation, 4 h after the last injection of RS504393 on
the 7th day post-CCI. Total RNAwas extracted according to
the method described by Chomczynski and Sacchi
(Chomczynski and Sacchi 1987) using TRIzol reagent
(Invitrogen). A NanoDrop ND-1000 spectrometer
(NanoDrop Technologies, Wilmington, USA) was used to
measure the RNA concentration in all probes. Reverse tran-
scription was performed at 37 °C for 60 min using Omniscript
reverse transcriptase (Qiagen Inc., Hilden, Germany) on 2 μg
of total RNA from the tissue. The reaction was performed in
the presence of an RNAse inhibitor (rRNasin, Promega,
Mannheim, Germany) and oligo (dT16) primer (Qiagen Inc.,
Hilden, Germany). The resulting cDNAwas diluted 1:10 with
H2O, and approximately 50 ng of cDNA from each individual
animal was used for each quantitative real-time PCR (RT-
qPCR) reaction. The RT-qPCR was performed using Assay-
On-Demand TaqMan probes, according to the manufacturer^s
protocol (Applied Biosystems, Foster City, CA, USA), and
run in an iCycler device (Bio-Rad, Hercules, Warsaw,
Poland). A standard dilution curve determined the amplifica-
tion efficiency for each assay. The following TaqMan primers
and probes were used: Rn01527838_g1 (HPRT,
hypoxanthine-guanine phosphoribosyltransferase);
Rn01423590_m1 (CD40, cluster of differentiation 40);
Rn00580555_m1 (CCL2, C-C motif chemokine ligand 2);
Rn01637698_s1 (CCR2, C-C chemokine receptor type 2);
Rn00566700_m1 (IL-1alpha, interleukin 1 alpha);
Rn00580432_m1 ( IL-1beta , in ter leukin 1 beta) ;
Rn02586400_m1 (IL-1RA, interleukin 1 receptor antagonist);
Rn00565482_m1 (IL-1R1, interleukin 1 receptor type 1);
Rn01422083_m1 (IL-18, interleukin 18); Rn00584495_q1
(IL-18BP, interleukin 18 binding protein); RN01437151_m1
(IL-18R, interleukin 18 receptor); Rn00561420_m1 (IL-6, in-
terleukin 6); Rn00563409_m1 (IL-10, interleukin 10); and
Rn00561646_m1 (iNOS, inducible nitric oxide synthase). A
standard dilution curve was used to determine the amplifica-
tion efficiency for each assay (between 1.7 and 2). The cycle
threshold values were calculated automatically by CFX
Manager v.2.1 software according to the default parameters.
RNA content was calculated as 2 - (threshold cycle). HPRT
transcript level was not significantly changed in the CCI-
exposed rats (Mika et al. 2010) and therefore, served as an
adequate housekeeping gene.
Analysis of Protein Level (Western Blot)
Ipsilateral fragments of the dorsal part of the lumbar (L4-L6)
spinal cord and the DRG (L4-L6) were collected immediately
after decapitation, 6 h after the last injection of RS504393 on
the 7th day post-CCI. First, tissue lysates were collected in
RIPA buffer with a protease inhibitor cocktail, and then the
reaction mixtures were cleared by centrifugation (14,000×g
for 30 min at 4 °C). All samples (20 μg of protein) were heated
in a loading buffer (4× Laemmli Buffer, Bio-Rad, Warsaw,
Poland) for 5 min at 98 °C. Afterwards, all of them were
resolved on 4–15% Criterion™ TGX™ pre-cast polyacryl-
amide gels (Bio-Rad, Warsaw, Poland) and transferred to
Immune-Blot PVDF membranes (Bio-Rad, Warsaw, Poland)
with semi-dry transfer (30 min, 25 V). Using 5% non-fat dry
milk (Bio-Rad, Warsaw, Poland) in Tris-buffered saline with
0.1% Tween 20 (TBST), membranes were blocked for 1 h at
RT, washed in TBST, and incubated overnight at 4 °C with the
following primary antibodies: rabbit anti-Iba-1 (1:1000,
Proteintech), rabbit anti-CCL2 (1:500, antibodies-online), rab-
bit anti-CCR2 (1:500, Abcam), mouse anti-CD4 (1:1000,
R&D Systems), rabbit anti-CD8 (1:500, Santa Cruz), mouse
anti-IL-1alpha (1:1000, Novus Biologicals), rabbit anti-IL-
1beta (1:1000, Abcam), rabbit anti-IL-1RA (1:1000, Abcam),
rabbit anti-IL-1R1 (1:1000, Sigma Aldrich), rabbit anti-IL-18
(1:1000, R&D Systems), rabbit anti-IL-18BP (1:1000, Novus
Biologicals), rabbit anti-IL-18R (1:1000, Abcam), rabbit anti-
IL-6 (1:500, Invitrogen), rabbit anti-IL-10 (1:500, Invitrogen),
rabbit anti-iNOS (1:500, Santa Cruz) and mouse anti-GAPDH
(1:5000, Millipore). Then, they were incubated for 1 h in
horseradish peroxidase-conjugated anti-rabbit or anti-mouse
secondary antibodies at a dilution of 1:5000. To dilute the
primary and secondary antibodies, solutions from a
SignalBoost™ Immunoreaction Enhancer Kit (Merck
Millipore Darmstadt, Germany) were used. The membranes
were washed 2 times for 2 min and 3 times for 5 min each with
TBST. The final step was the detection of immunocomplexes
conducted using the Clarity™ Western ECL Substrate (Bio-
Rad, Warsaw, Poland) and visualized using a Fujifilm LAS-
4000 FluorImager system. To quantify the relative levels of
immunoreactivity, Fujifilm Multi Gauge software was used.
Statistical Analyses
The behavioral tests analyses (Figs. 2 and 7) are presented in
grams and seconds as the mean ± standard error of the mean
(SEM). One-way analysis of variance (ANOVA) was used to
evaluate the experimental results. Differences between groups
were analyzed with Bonferroni’s post-hoc test. ***p < 0.001
indicates differences between naive rats and V-treated or RS-
treated; ###p < 0.001 indicates differences vs. V-treated CCI-
exposed rats; &&&p < 0.001 indicates differences vs. RS-
treated CCI-exposed rats; ^^^p < 0.001 indicates differences
between V + M- or V + B-treated vs. RS + M- or RS + B-
treated, CCI-exposed rats.
The biochemical data analyses (Figs. 1 and 3, 4, 5 and 6)
are presented as the fold change compared to naive rats on the




Scheme 1 All behavioral experiments were preceded by intrathecal
implantation of catheters since all drugs were administered via
intrathecal (i.t.) injection. One week after implantation, all rats were
subjected to sciatic nerve chronic constriction injury (CCI; day 0). a The
single injection of RS504393 (20 μg/5 μl) or vehicle was performed
7 days after CCI after which behavioral tests were conducted 30 min
(von Frey) and 35 min (cold plate) (data presented on Fig. 2a and c). b
The repeated injection of RS504393 (20 μg/5 μl) or vehicle were provided
once a day 16 h (day −1) and 1 h (day 0) before CCI and for 7 next days.
On the 7th day post-CCI behavioral tests were performed 30 min (von
Frey) and 35 min (cold plate) after drug administration and then 4 h (for
RT-qPCR analysis) or 6 h (for Western blot analysis) after the last RS/V
injection the tissue was collected (data presented on Fig. 2b and d). c
Additionally, the coadministration of repeated RS504393 with opioids
were performed. The group of chronically RS- or V-treated rats received
on the 7th day after CCI (approximately 60 min after RS/V injection) a
single injection of morphine or buprenorphine (2.5 μg/5 μl), and then, the
von Frey test (30 min) and the cold plate test (35 min) were performed
(data presented on Fig. 7a and b).Abbreviations: CCI, chronic constriction
injury; DRG, dorsal root ganglia; i.t., intrathecal; RT-qPCR, quantitative
reverse transcriptase real-time polymerase chain reaction; RS, RS504393;
WB, Western blot; V, vehicle
results were obtained from three groups of rats: naive, V-
treated CCI-exposed and RS-treated CCI-exposed. The RT-
qPCR and Western blot analysis data are presented as the
mean ± SEM, which represents normalized averages. The in-
tergroup differences were analyzed using ANOVA with
Bonferroni^s multiple comparisons post-hoc test. *p < 0.05,
**p < 0.01 and ***p < 0.001 indicate differences between naive
rats and V-treated or RS-treated CCI-exposed rats; #p < 0.05,
##p < 0.01 and ###p < 0.001 indicate differences vs. V-treated
CCI-exposed rats.
All graphs and analyses were prepared using GraphPad
Prism 5 (GraphPad Software, La Jolla, CA, USA).
Results
The Time Course Changes in CD40, CCL2, CCR2mRNA
and Iba-1, CCL2, CCR2 Protein Levels in the Spinal Cord
and DRG as Measured on the 2nd, 7th and 14th Day
after CCI
In the spinal cord the mRNA level of CD40 and protein level
of Iba-1 had already been upregulated 3.9-fold (p < 0.001) and
2.15-fold (p < 0.01), respectively, 2 days after CCI (Fig. 1a
and d). Strong changes (p < 0.001) in both CD40 and Iba-1
were still measured on 7th (3.6-fold and 3.9-fold, respectively)
and 14th (2.4-fold and 2.6-fold, respectively) day post-CCI
(Fig. 1a and d). The protein level of CCL2 in the spinal cord
was significantly enhanced (2.8-fold, p < 0.001) on 2nd day
(Fig. 1e). Even stronger upregulation of CCL2 protein level
(4.0-fold, p < 0.001) was observed 7 days after CCI (Fig. 1e).
On day 14th post-CCI we observed significant upregulation of
both mRNA (86.3–fold, p < 0.01) and protein (2.9-fold,
p < 0.001) level of CCL2 (Fig. 1b and e). The protein level
of CCR2 at the spinal cord level had already been enhanced
(1.5-fold, p < 0.001) 2 days after CCI (Fig. 1f). Similar chang-
es (1.5-fold, p < 0.001) in CCR2 protein level were observed
on 7th day after CCI (Fig. 1f). On day 14th post-CCI we
observed significantly enhanced (4.1-fold, p < 0.001) CCR2
mRNA level (Fig. 1c) and no changes in protein level
(Fig. 1f).
In the DRG no significant changes of both CD40 and Iba-1
were observed on 2nd day post-CCI (Fig. 1g and j). The up-
regulation of CD40 (1.29-fold, of the p < 0.001) and Iba-1
(1.46-fold, p < 0.05) was observed 7 days after CCI. Enhanced
level of CD40 and Iba-1 lasted till 14th day (1.6-fold,
p < 0.001 and 1.38-fold, p < 0.05, respectively) post-CCI
(Fig. 1g and j). The mRNA and protein level of CCL2 in the
DRGwas strongly upregulated (2.35-fold, p < 0.001 and 1.55-
fold, p < 0.001 respectively) on 2nd day and its enhanced
expression slightly decrease on 7th (2.05-fold, p < 0.001 and
1.2-fold, p < 0.05, respectively) and 14th (1.8-fold, p < 0.001
and 1.3-fold, p < 0.01, respectively) day post-CCI (Fig. 1h and
k). The protein level of CCR2 in the DRG was slightly en-
hanced (1.2-fold, p < 0.05) 2 days after CCI, and then no
changes were observed (Fig. 1l). Significantly enhanced
mRNA level of CCR2 was observed on 7th (1.9-fold,
p < 0.05) after CCI and even stronger upregulation on day
14th (3.2-fold, p < 0.001) (Fig. 1i).
The Influence of Single and Repeated Administration
of RS504393 on Pain-Related Behavior on the 7th Day
Post-CCI
In the von Frey test the paw ipsilateral to the injury signifi-
cantly responded to a stimulation in vehicle-treated CCI-ex-
posed rats (p < 0.001, Fig. 2a, b). Single injection of
RS504393 did not influence the level of pain-related behavior
induced bymechanical stimulus in CCI-exposed rats (Fig. 2a).
In contrast, pretreatment and repeated administration of
RS504393 significantly (p < 0.001) attenuated CCI-induced
tactile hypersensitivity 30 min after last injection (Fig. 2b).
In the cold plate test the paw ipsilateral to the injury signif-
icantly responded to a stimulation in vehicle-treated CCI-ex-
posed rats (p < 0.001, Fig. 2c, d). Single injection of
RS504393 did not influence the level of pain-related behavior
induced by thermal stimulus in CCI-exposed rats
(Fig. 2c). In contrast, pretreatment and repeated admin-
istration of RS504393 significantly (p < 0.001) attenuated
CCI-induced thermal hypersensitivity 30 min after last
injection (Fig. 2d).
The Influence of RS504393 on Iba-1, CD4 and CD8
Protein Levels in the Spinal Cord and DRG 7 days
after CCI
Iba-1 protein level was upregulated 2.7-fold (p < 0.001)
in the spinal cord in CCI-exposed rats compared with
naive rats (Fig. 3a). RS504393 decreased 1.6-fold the
spinal protein level of Iba-1 (p < 0.05, Fig. 3a). No
changes were observed in the level of CD4 in vehicle-treated
and RS504393-treated CCI-exposed rats (Fig. 3b). Similarly,
the protein level of CD8 also remains unchanged in the spinal
cord (Fig. 3c).
In the DRG, the protein level of Iba-1 was upregu-
lated 1.3-fold (p < 0.001), in the vehicle-treated CCI-
exposed rats compared with naive rats (Fig. 3d).
RS504393 significantly decreased (1.3-fold, p < 0.001)
the spinal level of Iba-1 (Fig. 3d). The protein level of
CD4 was upregulated in the DRG 1.6-fold (p < 0.001)
in the CCI-exposed rats compared with naive rats
(Fig. 3e) and RS504393 treatment did not influence
these changes (Fig. 3e). CD8 protein level was down-
regulated 1.7-fold (p < 0.001) in the DRG in the CCI-exposed
rats compared with naive rats; however RS504393 treatment
prevented these changes (p < 0.05; Fig. 3f).

The Influence of RS504393 on IL-1alpha, IL-1beta,
IL-1RA and IL-1R1 mRNA and Protein Levels
in the Spinal Cord and DRG 7 days after CCI
In the spinal cord, no changes were observed in the mRNA
and protein levels of IL-1alpha (Fig. 4a and e) in vehicle-
treated CCI-exposed rats compared with naive rats.
RS504393 increased 1.3-fold (p < 0.01) the protein level of
IL-1alpha (Fig. 4e); however, the mRNA level remained un-
changed (Fig. 4a) in the spinal cord. IL-1beta mRNA and
protein levels were upregulated 34.4-fold (p < 0.001) and
1.4-fold (p < 0.01), respectively in the spinal cord (Fig. 4b
and f) in the CCI-exposed rats compared with naive rats.
RS504393 decreased 2.9-fold (p < 0.01) the mRNA and
1.75-fold (p < 0.001) protein spinal levels of IL-1beta
(Fig. 4b and f, respectively). IL-1RA mRNA level was
increased 4.85-fold (p < 0.001, Fig. 4c) in the spinal
cord; however, no changes were observed in the protein
level (Fig. 4g) in the CCI-exposed rats compared with
naive rats. RS504393 decreased 2.4-fold (p < 0.01) the
spinal mRNA level of IL-1RA (Fig. 4c) but did not
influence the protein level (Fig. 4g). IL-1R1 mRNA
level was increased 3.6-fold (p < 0.01, Fig. 4d) in the
spinal cord in the CCI-exposed rats compared with na-
ive rats, but no changes were observed in the protein
level (Fig. 4h). Although RS504393 did not influence
the mRNA level (Fig. 4d), it decreased the protein level
of IL-1R1 1.5-fold (p < 0.01) in the spinal cord
(Fig. 4h).
In the DRG, the mRNA and protein levels of IL-1alpha
were upregulated 62.1-fold (p < 0.001) and 1.65-fold
(p < 0.001), respectively (Fig. 4i and m), in the vehicle-
treated CCI-exposed rats compared with naive rats.
RS504393 did not influence the mRNA and protein levels of
IL-1alpha in the DRG (Fig. 4i and m, respectively). IL-1beta
mRNA and protein levels were upregulated in the DRG 11.6-
fold (p < 0.001) and 1.1-fold (p < 0.05), respectively (Fig. 4j
and n), in the CCI-exposed rats compared with naive rats.
RS504393 reduced the mRNA (1.6-fold, p < 0.05) and protein
(1.2-fold, p < 0.001) levels of IL-1beta in the DRG (Fig. 4j and
n, respectively). IL-1RA mRNA level was increased 36-fold
(p < 0.001, Fig. 4k) in the DRG in the CCI-exposed rats
compared with naive rats, although no changes were observed
in the protein level (Fig. 4o). RS504393 downregulated the
mRNA (3.6-fold, p < 0.05) and protein (1.3-fold, p < 0.001)
levels of IL-1RA in the DRG (Fig. 4k and o, respectively). IL-
1R1 mRNA level was increased 6-fold p < 0.001 Fig. 4l) in
the CCI-exposed rats compared with naive rats, whereas the
protein level of IL-1R1 was decreased 1.4-fold (p < 0.001,
Fig. 4p) in the DRG. RS504393 did not influence the level
of IL-1R1 (Fig. 4l and p).
The Influence of RS504393 on IL-18, IL-18BP and IL-18R
mRNA and Protein Levels in the Spinal Cord and DRG
7 days after CCI
IL-18 mRNA and protein levels were upregulated (p < 0.001)
in the spinal cord 2.95-fold (Fig. 5a) and 2.6-fold (Fig. 5d),
respectively, in the CCI-exposed rats compared with naive
rats. RS504393 reduced the mRNA 1.1-fold (p < 0.05) and
Fig. 1 The time course changes in CD40, CCL2, CCR2 mRNA (a–c, g–
i) and Iba-1, CCL2, CCR2 protein (d–f, j–l) levels in the spinal cord (a–f)
and DRG (g–l) tissue on 2nd, 7th, and 14th days after chronic constriction
injury (CCI) in rats. The data are presented as the mean ± SEMof 5–8 and
5–6 samples per group in RT-qPCR and Western blot analysis, respec-
tively. The intergroup differences were analyzed using ANOVA with
Bonferroni^s multiple comparisons test.* p < 0.05, **p < 0.01 and
***p < 0.001 indicate differences between naive rats and CCI-exposed
rats. Abbreviations: CCI, chronic constriction injury; N, naive
Fig. 2 The influence of the single (5–8 rats per group; a, c) and repeated
(14–20 rats per group; b, d) administration of RS504393 (RS; 20 μg/5 μl;
i.t.; 16 h and 1 h before CCI and then once a day for 7 days) on pain-related
behavior (a, b von Frey test; c, d, cold plate test) on the 7th day post-CCI,
30 min after RS or V injection. Tactile and thermal hypersensitivity were
assessed at 30 min and 35 min, respectively. The data are presented as the
mean ± SEM. The horizontal dotted line shows the cut-off value. The
intergroup differences were analyzed using ANOVA with Bonferroni^s
multiple comparisons test. ***p < 0.001 indicates differences between naive
rats and V-treated/RS-treated CCI-exposed rats; ###p < 0.001 indicates dif-
ferences vs. V-treated CCI-exposed rats. Abbreviations; CCI, chronic con-
striction injury; N, naive; RS, RS504393; V, vehicle
protein 2.1-fold (p < 0.001) levels of IL-18 in the spinal cord
(Fig. 5a and d, respectively). IL-18BP mRNA level was in-
creased 1.6-fold (p < 0.001, Fig. 5b) in the CCI-exposed rats
compared with naive rats, but no changes were observed in the
protein level of IL-18BP (Fig. 5e). RS504393 decreased the
mRNA 1.1-fold (p < 0.05) and increased the protein 1.2-fold
(p < 0.01) spinal levels of IL-18BP (Fig. 5b and E). IL-18R
mRNA and protein levels were upregulated in the spinal cord
2.4-fold (p < 0.05, Fig. 5c) and 1.5-fold (p < 0.001, Fig. 5f) in
the CCI-exposed rats compared with naive rats. Although
RS504393 did not influence the mRNA IL-18R level
(Fig. 5c), whereas it decreased the protein level 1.6-fold
(p < 0.001, Fig. 5f).
In the DRG, IL-18 mRNA and protein levels were upreg-
ulated 3.9-fold (p < 0.001, Fig. 5g) and 1.6-fold (p < 0.01,
Fig. 5j), respectively, in the CCI-exposed rats compared with
naive rats. RS504393 reduced the mRNA 1.7-fold (p < 0.001)
and protein 1.45-fold (p < 0.05) levels of IL-18 in the DRG
Fig. 3 The influence of the repeated administration of RS504393 (RS;
20 μg/5 μl; i.t.; 16 h and 1 h before CCI and then once a day for 7 days)
on protein (a–f) levels of Iba-1 (a, d), CD4 (b, e), CD8 (c, f) in the spinal
cord and DRG on the 7th day after CCI. The data are presented as the mean
fold changes of control ± SEM (5–9 samples per group). The intergroup
differences were analyzed using ANOVAwith Bonferroni’s multiple com-
parisons test. ***p < 0.001 indicate differences between naive rats and V-
treated/RS-treated CCI-exposed rats. #p < 0.05 and ###p < 0.001 indicate
differences vs. V-treated CCI-exposed rats. Abbreviations: CCI, chronic
constriction injury; N, naive; V, vehicle; RS, RS504393
(Fig. 5g and j, respectively). IL-18BP mRNA level was in-
creased 1.9-fold (p < 0.001, Fig. 5h) in the CCI-exposed rats
compared with naive rats, but the protein level of IL-18BP
was decreased 1.2-fold (p < 0.05, Fig. 5k). RS504393 reduced
the mRNA 1.5-fold (p < 0.05) and protein 1.6-fold (p < 0.001)
levels of IL-18BP in the DRG (Fig. 5h and k). IL-18R mRNA
level was upregulated 2.2-fold (p < 0.05, Fig. 5i) in the DRG,
whereas no changes were observed in the protein level
(Fig. 5l) in the CCI-exposed rats compared with naive rats.
Although RS504393 did not influence the mRNA IL-18R
level (Fig. 5i) in the DRG, but it decreased the protein level
1.4-fold (p < 0.001, Fig. 5l).
The Influence of RS504393 on IL-6, IL-10 and iNOS
mRNA and Protein Levels in the Spinal Cord and DRG
7 days after CCI
IL-6 mRNA and protein levels were upregulated in the spinal
cord 24.7-fold (p < 0.001, Fig. 6a) and 1.2-fold (p < 0.05,
Fig. 6d), respectively, in the CCI-exposed rats compared with
naive rats. RS504393 diminished the protein level of IL-6 1.3-
fold (p < 0.01, Fig. 6d) and did not influence the mRNA level
(Fig. 6a). IL-10 mRNA level was upregulated 13.4-fold
(p < 0.001, Fig. 6b) in the CCI-exposed rats compared with
naive rats; however, the protein level was downregulated 1.2-
fold (p < 0.01, Fig. 6e). RS504393 decreased the mRNA 2.48-
fold (p < 0.01) and did not influence the protein level of IL-10
at the spinal cord level (Fig. 6b and e). The mRNA and protein
levels of iNOS were upregulated 7.7-fold (p < 0.05, Fig. 6c)
and 1.8-fold (p < 0.001, Fig. 6f), respectively, at the spinal
cord level in the CCI-exposed rats compared with naive rats.
RS504393 decreased the mRNA (9.6-fold, p < 0.05) and pro-
tein levels (1.3-fold, p < 0.01) of iNOS in the spinal cord
(Fig. 6c and f, respectively).
In the DRG, IL-6 mRNA and protein level was up-
regulated 183.6-fold (p < 0.001, Fig. 6g) and 1.7-fold
(p < 0.001, Fig. 6j), respectively, in the CCI-exposed
rats compared with naive rats. RS504393 diminished
the mRNA (2.3-fold, p < 0.01) and protein (1.21-fold,
p < 0.05) levels of IL-6 (Fig. 6g and j, respectively).
IL-10 mRNA level was upregulated 26.7-fold (p < 0.05,
Fig. 6h) in the CCI-exposed rats compared with naive
rats, but no changes were observed in the protein level
(Fig. 6k). RS504393 decreased the mRNA (3.3-fold,
p < 0.05, Fig. 6h) and did not influence the protein
level of IL-10 in the DRG (Fig. 6k). The mRNA level
of iNOS in the DRG was upregulated 154.9-fold
(p < 0.001, Fig. 6i), although no changes were observed
in the protein level (Fig. 6l) in the CCI-exposed rats
compared with naive rats. RS504393 decreased the
mRNA (5.3-fold, p < 0.05) and did not influence the
protein level of iNOS in the DRG (Fig. 6i and l,
respectively).
The Influence of the Repeated Administration
of RS504393 on Opioid Effectiveness on the 7th Day
Post-CCI
In von Frey test the single injections of the respective opioids
induced similar analgesic effects as RS504393. The combined
administration of RS504393 and morphine or buprenorphine
resulted in substantially more effective analgesia (p < 0.001,
Fig. 7a). In cold plate test the single injections of respective
opioids induced lower analgesic effects than the CCR2 antag-
onist. The combined administration of RS504393 and mor-
phine or buprenorphine resulted in substantially enhanced an-
algesic effects (p < 0.001, Fig. 7b).
Discussion
It has been previously demonstrated that in the CCI model a
strong tactile and thermal hypersensitivity developed on day 2
and lasted until day 14 after sciatic nerve injury (Pilat et al.
2016; Jurga et al. 2016). Similar time course is observed in the
microglial cells activation, with the strongest upregulation of
Iba-1 on day 7 post-CCI (Pilat et al. 2016; Jurga et al. 2016),
which we also confirmed in our current study. Additionally,
we revealed simultaneous upregulation of spinal protein level
of CCL2 and CCR2 on 2nd and 7th day after CCI. In DRG the
strongest upregulation of protein level of both, CCL2 and
CCR2 was observed on 2nd day post-CCI and in case of
CCL2 lasted until day 14th.
Our behavioral experiments demonstrated that repeated,
but not single, intrathecal administration of RS504393 not
only attenuated tactile and thermal hypersensitivity but also
enhanced analges ic proper t ies of morphine and
buprenorphine. These results complemented our previous
findings describing the analgesic effects of RS504393 and
its beneficial influence on CCI-elevated spinal upregulation
of CCR2 and CCL2 under neuropathy (Piotrowska et al.
2016a). Our results are in agreement with others, showing that
single intracisternal injections of CCR2 antagonist reduced
neuropathic pain induced by inferior alveolar nerve transec-
tion (Zhang et al. 2012) and lumbar disc herniation (Zhu et al.
2014). Importantly, our study is, to our knowledge, the first to
identify that chronic administration of RS504393 significantly
enhanced opioid effectiveness in a rat neuropathic pain model.
We hypothesize that the beneficial properties of RS504393
resulted from antagonizing CCR2, as it has been shown in
our previous paper (Piotrowska et al. 2016a) and also in other
publications (Berkhout et al. 2003; Pevida et al. 2012; Zhang
et al. 2012). Nevertheless, Mirzadegan et al. (2000) demon-
strated that RS504393 has also high affinity for α1a adrener-
gic receptor, which is known to be involved in the inflamma-
tory response occurring after peripheral nerve injury
(Drummond 2014) and important for generating and

transmitting neuropathic pain (Cheng et al. 2014). This might
be relevant for the analgesic effects which we observed, how-
ever it needs to be evaluated in the future.
The CCR2 is expressed by spinal microglia, astrocytes and
neurons, and CCL2 preferentially binds this receptor
(Kurihara and Bravo 1996; Jung et al. 2009; Gao and Ji
2010). The nociception can be increased directly by the acti-
vation of CCR2which is located on neurons. It was previously
showed that the intrathecal injection of CCL2 induced
hyperalgesia and ERK activation in superficial dorsal horn
neurons (Gao et al. 2009). Huang et al. (2014) showed that
CCL2 injected intrathecally induced the release of TNF-α,
which subsequently augmented an excitatory glutamatergic
transmission in substantia gelatinosa neurons.Moreover, stud-
ies with the patch clamp technique revealed that CCL2 in-
creased excitatory synaptic transmission as well as both
AMPA- and NMDA-induced currents (Gao et al. 2009).
Recently, Jin et al. (2015) showed that CCL2 was also signif-
icantly involved in the activation of spinal microglia associat-
ed with pain development. The intrathecal administration of
CCL2 neutralizing antibody reduced the expression of
microglial marker OX-42, and thus pain behavior (Jin et al.
2015). We observed similar effects in our previous studies,
where we used the CCR2 antagonist (Piotrowska et al.
2016a). Our new data suggest that on day 7 after the CCI,
the level of CCL2 increased in parallel with the upregulation
of Iba-1 and CD4-positive cells marker, and downregulation
of CD8-positive cells marker. Therefore, it seems that the
CCR2 activation increases nociception through both direct
and indirect manner.
Several studies have suggested that endogenous CCL2 is
one of the key mediators of spinal glia activation after nerve
injury (Thacker et al. 2009; Gao and Ji 2010; Parpura and
Zorec 2010; Zhao et al. 2012; Zhu et al. 2014). Baamonde
et al. (2011) showed that intrathecal administration of CCL2
provokes glial activation and the release of pronociceptive
molecules, such as IL-1beta, that together with CCL2, leads
to the sensitization of NMDA and AMPA receptors and con-
tributes to the development of thermal hypersensitivity. In
2016, Yang et al., suggested that CCL2 can promote microglia
cytokine secretion after nerve injury and that CCL2 RNAi
inhibited the expression of IL-1beta, IL-6 and tumor necrosis
factor alpha (TNF-α) by spinal microglia (Yang et al. 2016).
These findings are in agreement with our recently published
results showing that microglia inhibitor minocycline de-
creased CCI-induced pain and, in parallel, reduced spi-
nal CCL2/CCR2 signaling (Piotrowska et al. 2016a). We
have also reported that RS504393 prevented CCI-
induced spinal activation of microglia in a neuropathic
pain model (Piotrowska et al. 2016a). Here, we provide
the first evidence that a direct blockade of CCL2/CCR2
signaling modulates the level of some nociceptive fac-
tors in a rat model of neuropathic pain.
IL-1 family consists of numerous cytokines, sometimes
with opposing roles in nociceptive transmission under neurop-
athy. Our current study indicated that the CCI-induced devel-
opment of tactile and thermal hypersensitivity is associated
with the upregulation of IL-1beta in the spinal cord and
DRG, which is in agreement with previous reports (Pilat
et al. 2015). Additionally, we demonstrated for the first time
that RS504393 prevented the CCI-elevated upregulation of
pronociceptive IL-1beta in both examined structures, suggest-
ing that this can be one of the reasons of its strong analgesic
properties. These findings are in line with a previous study
that showed that RS504393 treatment significantly reduced
the lipopolysaccharide (LPS)-elevated level of IL-1beta in
mice with acute lung injury (Yang et al. 2010). Interestingly,
we also observed increased spinal protein level of
antinociceptive IL-1alpha after chronic injections of
RS504393, which likely contributes to the beneficial effects
of the CCR2 antagonist. Different situation is observed in the
DRG, where strong upregulation of antinociceptive IL-1alpha
induced by CCI was not changed by RS504393. The protein
level of antinociceptive IL-1RAwas not changed in both ex-
amined structures. However surprisingly, in the DRG it was
slightly decreased after RS504393 treatment, although the ex-
act mechanism underlying this phenomenon remains unclear
and requires further investigation. The aforementioned inter-
leukins act by binding to the functionally active IL-1R1
(Obreja et al. 2002). We observed that the CCI induced no
changes in IL-1R1 in the spinal cord and only slightly de-
creased its level in the DRG. After the nerve injury the pres-
ence of IL-1R1 on sensory neurons suggests the possibility
that IL-1beta might directly influence nociceptive transmis-
sion (Oka et al. 1994; Obreja et al. 2002), therefore IL-1RA
successfully decreases neuropathic pain (Pilat et al. 2015). We
assume that IL-1R1 is functionally active and that its turnover
might be enhanced in pathology. Thus, we did not observe
higher protein levels for this receptor, which is crucial for
pronociceptive IL-1beta. Our results are in agreement with
those obtained by Nadeau et al. (2011). In 1999, Sommer
et al., showed that epineural injections of anti-IL-1R1 antibod-
ies into the spinal cord reduced both pain-related behavior in
Fig. 4 The influence of the repeated administration of RS504393 (RS;
20μg/5μl; i.t.; 16 h and 1 h before CCI and then once a day for 7 days) on
mRNA (a–d, i–l) and protein (e–h,m–p) levels of IL-1alpha (a, e, i,m),
IL-1beta (b, f, j, n), IL-1RA (c, g, k, o) and IL-1R1 (d, h, l, p) in the spinal
cord and DRG on the 7th day after CCI. The data are presented as the
mean fold changes of control ± SEM of 4–7 and 5–9 samples per group in
RT-qPCR and Western blot analysis, respectively. The intergroup differ-
ences were analyzed using ANOVAwith Bonferroni’s multiple compar-
isons test. *p < 0.05, **p < 0.01 and ***p < 0.001 indicate differences
between naive rats and V-treated/RS-treated CCI-exposed rats. #p < 0.05,
##p < 0.01 and ###p < 0.001 indicate differences vs. V-treated CCI-ex-
posed rats. Abbreviations: CCI, chronic constriction injury; N, naive; V,
vehicle; RS, RS504393

mice following CCI (Sommer et al. 1999). Here, we demon-
strated that the CCR2 antagonist decreased the spinal protein
level of IL-1R1, which is crucial for impaired nociceptive
transmission under neuropathic pain.
IL-18 is another pleiotropic pronociceptive cytokine that
belongs to IL-1 superfamily (Pilat et al. 2016; Samarani
et al. 2016). The pro-inflammatory effects of IL-18 are tightly
controlled by its naturally occurring antagonist, called IL-
18BP, which is produced due to a negative feedback mecha-
nism (Dinarello and Fantuzzi 2003; Samarani et al. 2016).
Under physiological conditions, most IL-18 is bound with
IL-18BP and inactivated. Several studies demonstrated that
the development of neuropathic pain after peripheral nerve
injury is associated with spinal upregulation of mRNA and
the protein level of IL-18 and its specific receptor, IL-18R
(Miyoshi et al. 2008; Rojewska et al. 2014b; Popiolek-
Barczyk et al. 2015; Pilat et al. 2016). These findings are in
line with the results obtained in the current experiment. We
observed CCI-induced upregulation of IL-18 mRNA and pro-
tein levels in the spinal cord and DRG. Additionally, we pro-
vide the first evidence that blocking CCR2 by RS504393 sig-
nificantly prevented enhanced CCI-elevated upregulation of
pronociceptive IL-18 in both examined structures, which may
be crucial for its analgesic properties. Moreover, we showed
that the CCR2 antagonist decreased the protein level of IL-
18R in the spinal cord and DRG, which can be beneficial
because the pronociceptive IL-18 loses its main target. The
injection of IL-18BP results in strong antiallodynic and
antihyperalgesic effects in nerve-injured rats (Miyoshi et al.
2008; Pilat et al. 2016). The CCR2 antagonist significantly
increased the spinal protein level of antinociceptive IL-18BP,
which highly probable to exert a positive impact on nocicep-
tive transmission. However, the protein level of IL-18BP in
the DRG in RS504393-treated rats was even more decreased
than in the vehicle-treated group, which remains unclear. All
these results suggest that IL-18/IL-18R pathway is involved in
neuropathic pain development to a greater extent at the spinal
cord level compared to DRG.
Several studies have indicated that IL-6, which is secreted
mostly by macrophages and activated microglia, is strongly
increased after peripheral nerve injury. Therefore, it was
suggested as one of the first factors to play a key role in neu-
ropathic pain development (DeLeo et al. 1996; Mika et al.
2008; Lee et al. 2010). Here, we confirmed the strongly en-
hanced level of IL-6 in the spinal cord and DRG in CCI-
exposed rats. It was previously reported that administration of
IL-6 neutralizing antibodies reduced pain behavior in neuro-
pathic pain models (Schoeniger-Skinner et al. 2007; Mika et al.
2008; Lee et al. 2010). Yang et al. (2010) showed in an acute
lung injury model that the protein level of IL-6 in the broncho-
alveolar lavage fluid after LPS challenge was significantly low-
er in CCR2 knockout mice compared to C57BI/6 J mice.
Moreover, Nanki et al. (2001) suggested that CCL2 enhances
extracellular signal-regulated protein kinases 1 and 2 (ERK1/2)
activation due to CCR2 and, therefore, induces IL-6 production
by fibroblast-like synoviocytes in rheumatoid arthritis. We
demonstrated that RS504393 significantly reduced the protein
level of IL-6 in both examined structures, which might be one
of the reasons behind its beneficial properties.
The inducible nitric oxide synthase (iNOS) is a
pronociceptive factor that is expressed by both, microglia
and astrocytes (Tran et al. 1997; Possel et al. 2000), however
in the early phase of the neuropathic pain the main source of
iNOS are highly activated microglial cells (Popiolek-Barczyk
et al. 2015). Here, we observed the enhanced protein level of
iNOS in the spinal cord, but not in DRG in CCI-exposed rats.
Previously, we reported that minocycline, a microglial inhib-
itor, reduced the CCI-elevated protein level of iNOS (Makuch
et al. 2013). Importantly, in our current study, we also dem-
onstrated that RS504393 significantly decreased the level of
iNOS at the spinal cord level, which might be a consequence
of its inhibition of microglial cell activation, as we recently
reported (Piotrowska et al. 2016a).
IL-10 is an example of an antinociceptive cytokine, which
exhibits increased mRNA levels after sciatic nerve injury, as
previously described (Mika et al. 2008; Rojewska et al.
2014b). These findings are in line with our current results, in
which we observed increased mRNA levels of IL-10 in the
spinal cord and DRG. It was suggested that IL-10 may interact
with microglia through an inhibition of pronociceptive cyto-
kine release, e.g., IL-1beta, IL-6, and TNF-alpha (Relton and
Rothwell 1992; Sawada et al. 1999). However, RS504393
decreased the mRNA level of IL-10 but did not influence
the protein level in both examined structures.
Opioids are widely used in treatment of chronic pain.
Nevertheless, in the neuropathic pain, opioids exhibit lower
effectiveness than in other pain conditions (Watkins et al.
2005; Szczudlik et al. 2014). The mechanism underlying this
phenomenon is still poorly understood. Several studies reported
that morphine analgesic properties are influenced by profound-
ly activated microglial cells that release pronociceptive factors
during neuropathic pain (Ledeboer et al. 2005; Mika et al.
2007, 2009; Rojewska et al. 2014a, b; Zhang et al. 2015). It
was demonstrated that chronic administration of minocycline
Fig. 5 The influence of the repeated administration of RS504393 (RS;
20μg/5μl; i.t.; 16 h and 1 h before CCI and then once a day for 7 days) on
mRNA (a–c, g–i) and protein (d–f, j–l) levels of IL-18 (a, d, g, j), IL-
18BP (b, e, h, k) and IL-18R (c, f, i, l) in the spinal cord and dorsal root
ganglia on the 7th day after CCI. The data are presented as the mean fold
changes of control ± SEM of 4–7 and 5–9 samples per group in RT-qPCR
and Western blot analysis, respectively. The intergroup differences were
analyzed using ANOVA with Bonferroni’s multiple comparisons test.
*p < 0.05, **p < 0.01 and ***p < 0.001 indicate differences between naive
rats and V-treated/RS-treated CCI-exposed rats. #p < 0.05, ##p < 0.01 and
###p < 0.001 indicate differences vs. V-treated CCI-exposed rats.
Abbreviations: CCI, chronic constriction injury; N, naive; V, vehicle;
RS, RS504393

delayed the development of morphine tolerance due to a reduc-
tion in spinal cord expressions of IL-1beta and IL-18 (Mika
et al. 2009; Rojewska et al. 2014b; Zhang et al. 2015).
Thereby, it was postulated that cytokines may modulate opioid
receptor activity, and the excessive production of interleukins,
such as IL-1beta and IL-18, might be of key importance for
decreasing the opioid analgesic efficacy observed in neuropath-
ic pain therapy (Johnston et al. 2004; Pilat et al. 2015, 2016).
Several studies have indicated that opioid signaling is connect-
ed not only with interleukins but also with chemokines. Zhao
et al. (2012) showed that chronic administration of morphine
increased spinal CCL2, and its neutralizing antibody reduced
morphine-induced spinal microglial activation and morphine
tolerance. Moreover, a selective agonist of the μ opioid recep-
tor (DAMGO) enhanced the expressions of CCL2, CCL5 and
CXCL10 in human peripheral blood mononuclear cells
(Wetzel et al. 2000). The overexpression of CXCL10 due to
activation of CXCR3 and Gi protein results in an attenuation of
opioid-induced analgesia. However, blocking CXCL10 spinal
function enhanced the morphine antinociceptive properties in
rats with cancer-induced bone pain (Ye et al. 2014). Thus,
increasing evidence points to cross-talk between opioid and
chemokine receptors, which both belong to the G-protein cou-
pling receptors (GPCRs) superfamily. The fundamental mech-
anism governing the function of GPCRs is desensitization.
Several chemokines (e.g., CCL2, CCL5, CXCL12, and
CX3CL1) are known to interfere with the analgesic effects
induced by opioids due to heterologous desensitization
(Szabo et al. 2002; Chen et al. 2007). Szabo et al. (2002) re-
ported that desensitization of the μ opioid receptor by CCL5
and CXCL12 disrupted the balance between analgesia and
algesia. Previously, we reported that a CCR5 antagonist
(maraviroc) enhanced the analgesic potency of morphine and
buprenorphine (Kwiatkowski et al. 2016), which was associat-
ed with the lower levels of pronociceptive interleukins
(Piotrowska et al. 2016b). In the current study, we demonstrat-
ed that CCR2 antagonist (RS504393) also enhanced the anal-
gesic potency of morphine and buprenorphine in neuropathic
rats. These effects correspond well with the reduction in CCI-
elevated levels of CCL2 (Piotrowska et al. 2016a) and
pronociceptive interleukins, such as IL-1beta, IL-18 and IL-6.
A probable mechanism underlying the beneficial properties of
Fig. 7 The influence of the repeated administration of RS504393 (RS;
20μg/5μl; i.t.; 16 h and 1 h before CCI and then once a day for 7 days) on
pain-related behavior (A, von Frey test; B, cold plate test) and the
analgesic effects of morphine (M; 2.5 μg/5 μl; single dose i.t.; on the
7th day post-CCI, 60 min after RS or V injection) and buprenorphine (B;
2.5μg/5μl; single dose i.t.; on the 7th day post-CCI, 60min after RS or V
injection) in CCI-exposed rats. Tactile and thermal hypersensitivity were
assessed at 30 min and 35 min, respectively, after the last RS504393
injection and once again after single morphine or buprenorphine
injections. The data are presented as the mean ± SEM of 5–14 rats per
group. The horizontal dotted line shows the cut-off value. The intergroup
differences were analyzed using ANOVA with Bonferroni^s
multiple comparisons test. ###p < 0.001 indicates differences vs.
V + V-treated CCI-exposed rats; &&&p < 0.001 indicates
differences vs. RS + V-treated CCI-exposed rats; ^^^p < 0.001
indicates differences between V + M- or V + B-treated vs. RS + M- or
RS + B-treated, CCI-exposed rats. Abbreviations: B, buprenorphine;
CCI, chronic constriction injury; M, morphine; N, naive; RS,
RS504393; V, vehicle
Fig. 6 The influence of the repeated administration of RS504393 (RS;
20μg/5μl; i.t.; 16 h and 1 h before CCI and then once a day for 7 days) on
mRNA (a–c, g–i) and protein (d–f, j–l) levels of IL-6 (a, d, g, j), IL-10 (b,
e, h, k) and iNOS (c, f, i, l) in the spinal cord and DRG on the 7th day after
CCI. The data are presented as themean fold changes of control ± SEMof
4–7 and 5–9 samples per group in RT-qPCR and Western blot analysis,
respectively. The intergroup differences were analyzed using ANOVA
with Bonferroni’s multiple comparisons test. *p < 0.05, **p < 0.01 and
***p < 0.001 indicate differences between naive rats and V-treated/RS-
treated CCI-exposed rats. #p < 0.05 and ##p < 0.01 indicate differences vs.
V-treated CCI-exposed rats. Abbreviations: CCI, chronic constriction in-
jury; N, naive; V, vehicle; RS, RS504393
RS504393 is the inhibition of microglial cell activation
(Piotrowska et al. 2016a), responsible for releasing
pronociceptive factors, which negatively influence opioid-
induced analgesia. In our opinion, the activated spinal microg-
lia is a key factor in the development of neuropathic pain, as
well as in the efficacy of different opioid analgesics. We previ-
ously showed (Mika et al. 2014; Popiolek-Barczyk et al. 2014)
that microglial inhibitor, minocycline, enhances the effective-
ness of selective MOP, KOP and NOP, but not DOP ligands
under neuropathic pain conditions. In our experiment,
RS504393 acts as an inhibitor of microglial activation, there-
fore, it remains in agreement with our previously published
data that both morphine (ligand of MOP, DOP and KOP) and
buprenorphine (ligand ofMOP,DOP,KOP,NOP) effectiveness
is enhanced in a CCI model. However, the explanation of this
phenomenon requires further insightful research. Moreover,
this lets us assume that the enhancement of their effectiveness
is undoubtedly related toMOP andKOP receptors, as in case of
buprenorphine also with NOP. Furthermore, we hypothesize
that the CCR2 antagonist, by preventing CCI-elevated upregu-
lation of CCL2 and CCR2, inhibited heterologous desensitiza-
tion between opioid and chemokine receptors, although this
needs to be studied in the future.
Conclusion
We propose CCR2 as a promising target for the manipulation
of neuropathic pain. The low effectiveness of opioids in neu-
ropathic pain is associated with significant changes in the
production of pro- and antinociceptive factors. In our current
study, we observed that targeting CCR2 restores the analgesic
activities of morphine and buprenorphine. Simultaneously,
RS504393 prevented the CCI-induced upregulation of
pronociceptive factors, such as IL-1beta, IL-18, IL-6 and
iNOS, due to inhibition of microglial activation and increased
expression of antinociceptive IL-1alpha. This supports the hy-
pothesis that the pharmacological modulation of
neuroimmunological interactions via CCR2 may represent a
new strategy for effective polytherapy with opioids in patient
suffering from neuropathic pain.
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